Abstract
We wanted to establish the point prevalence of MS in Northern Ireland. Northern Ireland has been a known high-risk area for MS since the original work of Allison and Millar in 1951. Studies demonstrated a rising prevalence in 1951 of 41 (95% CI, 37 to 441, in 1961 of 57 (95% CI, 53 to 611, and in 1986 of 104 (95% CI, 85 to 128)/105 population for probable/early probable and latent disease. We surveyed four districts (area 2,030 km2, population 151,000). Case sources included Regional Neurology Service records, postal survey of general medical practitioners, hospital databases, MS charities, and MS respite facilities. We used the Poser and Allison and Millar criteria in diagnosis. From a provisional list of 402 patients, 254 (177 female, 77 male, ratio 2.3:l) were identified with definite or probable disease by the Poser criteria, prevalence 168.2/105 (95% CI, 147.5 to 188.9/105) with 34 suspected patients and an overall prevalence 190.7/105 (95% CI, 168.7 to 212.7/105). We interviewed and examined over 87% of these 288 patients. There were 246 patients classified as probable/early probable and latent by Allison and Millar, prevalence 162.9/105 (95% CI, 142.6 to 183.3/105). Seventy-six probable or definite patients had onset between 1985 and 1992 (estimated incidence, 6.5/105/yr). Age range of prevalent patients was 18 to 79 years (mean ± SD, 49.2 ± 13.3 years). Mean age at onset was 31.6 ± 10.1 years. Overall, 12.5% had primary progressive disease and 20% had benign MS. Northern Ireland has an extremely high and rising MS prevalence. This may reflect a true increase in disease incidence or may be explained by increasing survival, improved case ascertainment, increased disease awareness, or improved laboratory and radiologic diagnosis.
- © 1998 by the American Academy of Neurology.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
